Salidroside (Rhodioloside)

Description: Salidroside (Rhodioloside), a phenylpropanoid glycoside isolated from Rhodiola rosea, has been reported to have a broad spectrum of pharmacological properties. Salidroside inhibits the growth of various human cancer cell lines in concentration- and time-dependent manners, and the sensitivity to salidroside is different in those cancer cell lines. Salidroside could cause G1-phase or G2-phase arrest in different cancer cell lines, meanwhile, salidroside resultes in a decrease of CDK4, cyclin D1, cyclin B1 and Cdc2, and upregulates the levels of p27(Kip1) and p21(Cip1). Salidroside also alleviates cell viability loss and apoptotic cell death induced by H(2)O(2) stimulation in cultured NGF-differentiated PC12 cells by activating ERK1/2 pathway and inhibiting caspase-3 activation.

References: Cell Biol Toxicol. 2010 Dec; 26(6):499-507; J Mol Neurosci. 2010 Mar; 40(3):321-31; J Pharm Pharmacol. 2009 Oct; 61(10):1375-82.